Related Experiment Video
Updated: Feb 2, 2026
Author Spotlight: Advancing Metabolomics Analysis of Rare Hematopoietic Stem Cells
Published on: February 23, 2024
Hypophosphatasia: A rare disorder
Rodney W Hicks1, Leah Umnitz2, Diane C Seibert3
1College of Graduate Nursing Western University of Health Sciences, Pomona, California.
Insights
Hypophosphatasia is a rare metabolic bone disorder with varied inheritance patterns. Management focuses on complications, with new therapies emerging but some bone disease treatments contraindicated.
Area of Science:
- Metabolic bone disorders
- Genetics
- Pediatric endocrinology
Background:
- Hypophosphatasia is a rare, inherited metabolic disorder affecting bone development.
- It presents with infantile rickets, improves in adolescence, and recurs as osteopenia/osteoporosis in mid-life.
- Genetic counseling is crucial for at-risk families.
Purpose of the Study:
- To provide a comprehensive overview of Hypophosphatasia.
- To highlight the progressive nature and varied clinical manifestations.
- To discuss current management strategies and future therapeutic directions.
Main Methods:
- Literature review of Hypophosphatasia.
- Analysis of clinical presentation and inheritance patterns.
- Review of management guidelines and emerging therapies.
Main Results:
- Hypophosphatasia exhibits autosomal dominant or recessive inheritance.
- Clinical course includes infantile rickets and adult-onset osteopenia/osteoporosis.
- Long-term care requires multidisciplinary specialist involvement.
Conclusions:
- Hypophosphatasia necessitates lifelong monitoring and management.
- Careful consideration of contraindications for certain bone disease therapies is essential.
- Genetic consultation is vital for family planning and risk assessment.
Abstract:
Hypophosphatasia is a rare, progressive metabolic disorder inherited in either an autosomal dominant or an autosomal recessive fashion. Affected individuals may have unusual bone development. Infants may be diagnosed with infantile rickets. Symptoms then abate during adolescence, with bony abnormalities manifesting again as mid-life osteopenia or osteoporosis. Long-term management is focused on minimizing complications, so consultations and periodic visits with a variety of specialists is often warranted. New therapies are on the horizon, but some agents used to treat bone diseases are contraindicated in this population. At-risk relatives should be referred to genetic professionals to determine mode of inheritance and discuss options.
Related Concept Videos
02:18Intrinsically Disordered Proteins
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
01:30Other Disorders of Digestive System
01:27Panic Disorder